213 related articles for article (PubMed ID: 36341997)
1. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
2. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation.
Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK
bioRxiv; 2024 Jan; ():. PubMed ID: 37066260
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
4. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
5. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
6. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
7. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
8. DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma.
Olsen TK; Dyberg C; Embaie BT; Alchahin A; Milosevic J; Ding J; Otte J; Tümmler C; Hed Myrberg I; Westerhout EM; Koster J; Versteeg R; Ding HF; Kogner P; Johnsen JI; Sykes DB; Baryawno N
JCI Insight; 2022 Aug; 7(17):. PubMed ID: 35943801
[TBL] [Abstract][Full Text] [Related]
9. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Yu Y; Ding J; Zhu S; Alptekin A; Dong Z; Yan C; Zha Y; Ding HF
Cell Death Dis; 2021 Aug; 12(9):821. PubMed ID: 34462431
[TBL] [Abstract][Full Text] [Related]
11. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.
Abt ER; Rosser EW; Durst MA; Lok V; Poddar S; Le TM; Cho A; Kim W; Wei L; Song J; Capri JR; Xu S; Wu N; Slavik R; Jung ME; Damoiseaux R; Czernin J; Donahue TR; Lavie A; Radu CG
Cell Chem Biol; 2020 Feb; 27(2):197-205.e6. PubMed ID: 31734178
[TBL] [Abstract][Full Text] [Related]
13. Identification of DHODH as a therapeutic target in small cell lung cancer.
Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
15. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
17. The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.
Cuthbertson CR; Guo H; Kyani A; Madak JT; Arabzada Z; Neamati N
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1242-1252. PubMed ID: 33344900
[TBL] [Abstract][Full Text] [Related]
18. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Koundinya M; Sudhalter J; Courjaud A; Lionne B; Touyer G; Bonnet L; Menguy I; Schreiber I; Perrault C; Vougier S; Benhamou B; Zhang B; He T; Gao Q; Gee P; Simard D; Castaldi MP; Tomlinson R; Reiling S; Barrague M; Newcombe R; Cao H; Wang Y; Sun F; Murtie J; Munson M; Yang E; Harper D; Bouaboula M; Pollard J; Grepin C; Garcia-Echeverria C; Cheng H; Adrian F; Winter C; Licht S; Cornella-Taracido I; Arrebola R; Morris A
Cell Chem Biol; 2018 Jun; 25(6):705-717.e11. PubMed ID: 29628435
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
Berber B; Doluca O
Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
